Dual IL-17A, IL-17 F Inhibitor Bimzelx Should Have Some Impact in PsA Space
-
Dec 12, 2024
UCB, Inc.’s Bimzelx (bimekizumab-bkzx) recently gained FDA approval for the treatment of psoriatic arthritis (PsA), bringing a new mechanism of action to the therapeutic class. Industry experts say it may be challenging to break into the crowded space, but if successful, it could impact coverage of and prescribing for the class.
On Sept. 20, the FDA approved three more indications for Bimzelx for the treatment of adults with active PsA, adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation and adults with active ankylosing spondylitis. Two months later, on Nov. 20, the FDA gave the drug another approval, for the treatment of moderate-to-severe hidradenitis suppurativa.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.